Author Correction: Neoadjuvant durvalumab plus radiation versus durvalumab alone in stages I-III non-small cell lung cancer: survival outcomes and molecular correlates of a randomized phase II trial.
Nat Commun
; 15(1): 225, 2024 Jan 03.
Article
in En
| MEDLINE
| ID: mdl-38172131
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Type of study:
Clinical_trials
Language:
En
Journal:
Nat Commun
Year:
2024
Document type:
Article